The efficacy, safety, and tolerability of subcutaneous sumatriptan in
the acute treatment of cluster headache were investigated in a multice
nter study over a period of up to 1 year. A total of 2,031 attacks wer
e evaluated in 52 patients. Therapy was successful in 88% of all attac
ks. Freedom from pain within 15 minutes in more than 90% of all attack
s treated was reported by 42% of the patients, and no decline in effic
acy occurred during the course of the study. Adverse events were repor
ted by 62% of the patients.